Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb Randomised, Double-blind, Placebo-controlled, Multi-centre, Dose-ranging Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Due to Left Heart Disease (WHO Group 2)

NCT05737940 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05737940
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05737940 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb Randomised, Double-blind, Placebo-controlled, Multi-centre, Dose-ranging Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Due to Left Heart Disease (WHO Group 2)
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
April 24, 2023
Completion date
August 25, 2025
Enrollment
260 (actual)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure, pulmonary hypertension (world health organization group 2)